

NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, April 17, 2004 - 8:30 a.m. - 3:30 p.m.
Room: Churchill Ballroom A

Chair: Dr. Frances Shepherd

8:30 a.m. Results of NCIC 5-Year External Site Review F Shepherd

NON-SMALL CELL LUNG CANCER

8:45 a.m. **Surgical Adjuvant and Neoadjuvant Trials**

BR.10 - Adjuvant navelbine/cisplatin in Stage I-II NSCLC	T Winton
BR.16 - Randomized placebo controlled trial of adjuvant Selenium in completely resected stage I NSCLC (ECOG)	M Johnston
BR.19 - Randomized trial of adjuvant Iressa versus placebo after complete resection of Stage IB, II IIIA NSCLC	G Goss
BR.22 - Induction chemotherapy versus immediate surgery in Early stage NSCLC (SWOG)	Peter Ellis
BR.23 - Phase II trial of etoposide/cisplatin/XRT followed by Surgery and consolidation Taxotere for Pancoast tumours	S Laurie
ES.2 - Palliative radiation for esophageal cancer	R Wong

10:00 **COFFEE BREAK**

10:30 **Advanced NSCLC**

BR.13 - Chemotherapy/XRT vs Chemotherapy/XRT/Surgery for Stage IIIA(N2) NSCLC- Final report	G Darling
BR.15 Chemotherapy and radiotherapy +/- Iressa In Stage IIIB NSCLC (SWOG)	Y Ung
BR.18 - Taxol/carboplatin +/- BMS275291 in advanced NSCLC Final report	N Leigh
BR.21 - Randomized trial of Tarceva versus placebo as 2nd or 3rd line treatment of advanced NSCLC	F Shepherd
BR.17 - Randomized comparison of Tomudex/cisplatin versus Cisplatin alone in Malignant Mesothelioma (EORTC)	M Vincent

12:00-1:30 **LUNCH**

SMALL CELL LUNG CANCER

1:30 p.m. BR.20 - Randomized Phase II trial of ZD6474 versus placebo in responding patients with SCLC

A Arnold

SMALL CELL LUNG CANCER

PCI in NSCLC (RTOG)

A Sun

PCI in SCLC (RTOG)

A Sun

Randomized Phase II trial of Iressa versus standard combination chemotherapy as first-line treatment for N-SCLC

R Feld

ZD 2172 in Non-SCLC

G Goss

Randomized Phase II trial of new oral taxane in second-line Treatment of Non-SCLC

F Shepherd

2:45 p.m. **COFFEE BREAK**